Neo Ivy Capital Management Buys Shares of 4,424 DaVita Inc. (NYSE:DVA)

Neo Ivy Capital Management acquired a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 4,424 shares of the company's stock, valued at approximately $726,000.

A number of other hedge funds have also modified their holdings of the stock. Transcendent Capital Group LLC bought a new position in DaVita during the 3rd quarter valued at about $25,000. Blue Trust Inc. raised its stake in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. acquired a new position in shares of DaVita in the 2nd quarter worth approximately $43,000. Quarry LP acquired a new position in shares of DaVita in the 3rd quarter worth approximately $60,000. Finally, Point72 Hong Kong Ltd bought a new stake in DaVita during the 2nd quarter worth approximately $68,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 1.0 %

Shares of DVA stock traded down $1.60 on Thursday, reaching $153.90. 456,511 shares of the stock were exchanged, compared to its average volume of 810,685. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a one year low of $103.40 and a one year high of $169.51. The stock has a market cap of $12.62 billion, a PE ratio of 16.60, a P/E/G ratio of 0.90 and a beta of 0.90. The stock has a 50 day moving average price of $158.10 and a 200 day moving average price of $150.68.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.85 earnings per share. Equities research analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Insider Activity at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Barclays lifted their price target on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, DaVita has an average rating of "Hold" and an average target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.